Dren Bio raises $350 million to advance rare blood cancer antibody

Dren Bio, a California biotech, announced a $350 million financing round to fund late‑stage development and commercial preparation of its lead therapy, a CD94‑targeting monoclonal antibody known as dibotatug (DR‑01).\n\nThe round was oversubscribed and co‑led by Juvia Group and Lightspeed Venture Partners. It follows earlier fundraises of $65 million in 2022 and $60 million in 2020.\n\nDren Bio previously received a $600 million cash payment from Sanofi for its bispecific candidate DR‑0201 (now SAR448501). The new capital will support regulatory activities and market launch plans for the rare blood cancer indication.